The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review) (2023.12.5)
https://www.spandidos-publications.com/10.3892/or.2023.8675
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Lung cancer is currently the second most common type of cancer with the second incidence rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for ~85% of the total number of cases of lung cancers. Concerning the treatm
www.spandidos-publications.com
* 종류
1. Osimertinib (also named AZD9291) 타그리소
2. Almonertinib (also named HS-10296)
3. Furmonertinib (also named AST2818)
4. Olmutinib (also named HM61713)
5. Lazertinib (also named YH25448) 레락자
6. Nazartinib (also named EGF816)
7. Rociletinib (also named CO1686)
8. Other third-generation targeted drugs
1) abivertinib (AC0010)
2) naquotinib (ASP8273) w
3) rezivertinib (BPI-7711)
4) 그외 mavelertinib (PF-06747775) (65), limertinib (ASK120067) (66,67), befotertinib (D-0316) (68), olafertinib (CK-101/RK518), keynatinib (16), SH-1028 (69,70) and TAS-121 (71), which are all under development and trial.
'신약개발 소식, 해외 논문들' 카테고리의 다른 글
| 유전자가위 활용해 혈액에서 암 관련 유전자를 고감도로 검출하는 ʻSCOPEʼ 진단플랫폼 개발 (1) | 2024.11.13 |
|---|---|
| 타그리소 VS 레락자 (0) | 2024.09.13 |
| Rybrevant+ Lazertinib(Mariposa) (0) | 2024.09.11 |
| Amivantamab + lazertinib (CHRYSALIS-2) (0) | 2024.09.10 |
| 유한양행 렉라자, FDA 허가…비소세포폐암 1차 치료제 승인 (0) | 2024.09.09 |